VALIC Company I Health Sciences Fund (VCHSX)

22.75
Net Asset Value
+0.18%
1 Day
+4.45%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.09%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital growth. The fund normally invests at least 80% of its net assets in the common stocks of companies engaged in the research- development- production- or distribution of products or services related to health care- medicine- or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size- the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund may invest up to 35% of its total assets in foreign stocks- which include non-dollar denominated securities traded outside the U.S.

Performance

1 month+0.18% 3 years+8.01%
3 months+6.76% 5 years+19.63%
1 year+21.33% Since inception+11.53%
Data through --

Peer Comparisonvs. Health

 VCHSXCategory
Performance 5-yr return+19.63%+17.08%
Expense ratio1.09%1.20%
Risk 5 year sharpe ratio1.301.09
Net assets$817.5M$230.1M
Average market cap$23.8B$9.5B
Average P/E26.322.6
Portfolio turnover30%30%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyVALIC
Fund manager & tenureZiad Bakri / 1 Years
Minimal initial investment$0.00
Minimum IRA investment--

Holdings

U.S. stock93.58%
International stock4.69%
Other0.93%
Fixed income0.73%
Cash0.07%
Top 5 Sectors
Portfolio weighting
Healthcare 93.57%
Consumer service 1.09%
Industrial materials 0.89%
Financial service 0.35%
Hardware 0.19%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth6.64%
BDX Becton Dickinson and Co4.11%
ISRG Intuitive Surgical3.81%
VRTX Vertex Pharmaceuticals Inc3.13%
CI Cigna Corp2.79%
SAGE SAGE Therapeutics Inc2.37%
ANTM WellPoint2.22%
SYK Stryker Corp2.21%
A Agilent Technologies Inc2.15%
ALXN Alexion Pharmaceuticals Inc2.10%